ECOG performance status≥ 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—a systematic …
FG Dall'Olio, I Maggio, M Massucci, V Mollica… - Lung Cancer, 2020 - Elsevier
Objectives ICIs have been approved and are routinely administered regardless of
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - Elsevier
Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors
After decades of platinum-based chemotherapy for advanced small-cell lung cancer, there
has finally been a therapeutic advance. The combination of a platinum chemotherapy …
has finally been a therapeutic advance. The combination of a platinum chemotherapy …
EPSILoN: a prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort
A Prelaj, R Ferrara, SE Rebuzzi, C Proto, D Signorelli… - Cancers, 2019 - mdpi.com
Background: Beyond programmed death ligand 1 (PD-L1), no other biomarkers for
immunotherapy are used in daily practice. We previously created EPSILoN (Eastern …
immunotherapy are used in daily practice. We previously created EPSILoN (Eastern …
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score≥ 50% treated with front-line pembrolizumab
Objectives: We retrospectively analysed patients with advanced non-small-cell lung cancer
(NSCLC) harbouring high PD-L1 expression (> 50%) and treated with front-line …
(NSCLC) harbouring high PD-L1 expression (> 50%) and treated with front-line …
[HTML][HTML] Comparison of Prognostic Values of Seven Immune Indexes in Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab: How Effective Can They Be …
A Ulas, B Temel, FT Kos - Medicina, 2024 - mdpi.com
Background and Objectives: In this study, we evaluated the impact of seven immune indexes
on treatment response and survival outcomes in advanced non-small-cell lung cancer …
on treatment response and survival outcomes in advanced non-small-cell lung cancer …
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Introduction The safety of first-line (1L) durvalumab in patients with advanced nonsmall-cell
lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance …
lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance …
Immunotherapy in lung cancer: are the promises of long-term benefit finally met?
DL Kaen, N Minatta, A Russo, U Malapelle… - Immunotherapy, 2021 - Springer
Over the last few years, agents targeting immune checkpoints have shown potential to
improve therapeutic outcomes in patients with lung cancer in multiple clinical settings …
improve therapeutic outcomes in patients with lung cancer in multiple clinical settings …
[HTML][HTML] CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?
JC Benitez, J Remon, B Besse - Translational Lung Cancer …, 2019 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2019; 8
(Suppl 4): S464-S467| http://dx. doi. org/10.21037/tlcr. 2019.12. 26≥ 70 years. Patients with …
(Suppl 4): S464-S467| http://dx. doi. org/10.21037/tlcr. 2019.12. 26≥ 70 years. Patients with …